2025.May.01

Corporate

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology.

HOMEWhat’s NewNewsOBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Apr.29

OBI Pharma Unveils New ThiOBI® and HYPrOBI™ Platforms Showcasing Strong ADC Development Capabilities and Captivating Attention at AACR